Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

$7.52 +0.09 (+1.21%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$7.52 0.00 (0.00%)

As of 08:00 AM Eastern

Adaptive Biotechnologies - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Adaptive Biotechnologies in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for ADPT.

Consensus Price Target

$9.40
25.00% Upside

According to the 5 analysts' twelve-month price targets for Adaptive Biotechnologies, the average price target is $9.40. The highest price target for ADPT is $12.00, while the lowest price target for ADPT is $6.00. The average price target represents a forecasted upside of 25.00% from the current price of $7.52.

Get the Latest News and Ratings for ADPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Adaptive Biotechnologies and its competitors.

ADPT Analyst Ratings Over Time

Type	Current Forecast 4/2/24 to 4/2/25	1 Month Ago 3/3/24 to 3/3/25	3 Months Ago 1/3/24 to 1/2/25	1 Year Ago 4/3/23 to 4/2/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.40	$9.10	$6.75	$7.25
Forecasted Upside	25.00% Upside	12.35% Upside	9.05% Upside	143.29% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

ADPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ADPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adaptive Biotechnologies Stock vs. The Competition

Type	Adaptive Biotechnologies	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	25.00% Upside	19,857.32% Upside	19.03% Upside
News Sentiment Rating	Positive News See Recent ADPT News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	The Goldman Sachs Group 3 of 5 stars	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00	+16.13%
2/20/2025	Piper Sandler 2 of 5 stars	David Westenberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $11.00	+29.73%
2/13/2025	Scotiabank 5 of 5 stars	Sung Ji Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$10.00 ➝ $12.00	+44.67%
12/18/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$8.00 ➝ $9.00	+40.41%
8/2/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$5.00 ➝ $6.00	+36.99%
11/10/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/24/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$13.00 ➝ $10.00	+139.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:18 AM ET.

ADPT Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Adaptive Biotechnologies is $9.40, with a high forecast of $12.00 and a low forecast of $6.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADPT shares.
: According to analysts, Adaptive Biotechnologies's stock has a predicted upside of 25.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Adaptive Biotechnologies's stock had 1 upgrade by analysts.
: Adaptive Biotechnologies has been rated by research analysts at Piper Sandler, Scotiabank, and The Goldman Sachs Group in the past 90 days.
: Analysts like Adaptive Biotechnologies more than other "medical" companies. The consensus rating for Adaptive Biotechnologies is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ADPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ADPT) was last updated on 4/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target